US 12,076,350 B2
Fecal microbiota composition for use in reducing treatment-induced inflammation
Emilie Plantamura, Lyons (FR); Cyrielle Gasc, Lyons (FR); Benoît Levast, Lyons (FR); Lilia Boucinha, Lyons (FR); Corentin Le Camus, Lyons (FR); Carole Schwintner, Lyons (FR); and Hervé Affagard, Lyons (FR)
Assigned to MaaT PHARMA, Lyons (FR)
Appl. No. 17/261,532
Filed by MaaT PHARMA, Lyons (FR)
PCT Filed Jul. 19, 2019, PCT No. PCT/EP2019/069597
§ 371(c)(1), (2) Date Jan. 19, 2021,
PCT Pub. No. WO2020/016445, PCT Pub. Date Jan. 23, 2020.
Claims priority of application No. 18305997 (EP), filed on Jul. 20, 2018; and application No. PCT/FR2019/050522 (WO), filed on Mar. 8, 2019.
Prior Publication US 2021/0299188 A1, Sep. 30, 2021
Int. Cl. A61K 35/74 (2015.01); A61K 35/38 (2015.01)
CPC A61K 35/74 (2013.01) [A61K 35/38 (2013.01)] 19 Claims
 
1. A method for reducing an inflammation induced by anti-cancer therapy combined with antibiotherapy and/or hematopoietic stem cell transplantation (HSCT) in acute leukemia patients, comprising administering a human fecal microbiota composition to the individual,
wherein the proportion of some or all the following 15 genera is increased relative to the level before a fecal microbiota transfer (FMT): Blautia, Faecalibacterium, Alistipes, Eubacterium, Bifidobacterium, Ruminococcus, Clostridium, Coprococcus, Odoribacter, Roseburia, Holdemanella, Anaerostipes, Oscillibacter, Subdoligranulum and Butyrivibrio; and
wherein neopterin in a gut, C-Reactive Protein (CRP) in serum and/or ferritin in serum is decreased,
wherein the human fecal microbiota composition administered comprises some or all the following 15 genera: Blautia, Faecalibacterium, Alistipes, Eubacterium, Bifidobacterium, Ruminococcus, Clostridium, Coprococcus, Odoribacter, Roseburia, Holdemanella, Anaerostipes, Oscillibacter, Subdoligranulum and Butyrivibrio; and
wherein neopterin in a gut, C-Reactive Protein (CRP) in serum and/or ferritin in serum is decreased.